Efficacy and safety of Subetta add-on therapy in type 1 diabetes mellitus: The results of a multicenter, double-blind, placebo-controlled, randomized clinical trial

Abstract

ClinicalTrials.gov identifier: NCT01868594.

RETRACTED ARTICLE: New insights into the microscopic interactions associated with the physical mechanism of action of highly diluted biologics

“…In this work we have explored the underlying microscopic interactions and molecular changes that are associated with HD protein samples that have recently been shown to be effective in the treatment of a number of biological disorders 55 – 57 . These studies were also strongly motivated in response to the unexpected strong protein signals that the HD samples emit in the experimental THz region of the spectrum.…”

Drug discovery today: no molecules required

“…Release-active ‘drugs’ (RADs)1–24 are manufactured by a single Russian company called OOO ‘NPF ‘Materia Medica Holding’ (MMH) 25 26. According to the original patent by its founder and CEO Epstein et al ,27 these preparations consist of ‘ activated forms of ultra-low doses of antibodies conventionally designated as potentiated (dynamised) antibodies (by analogy with the terminology used in homeopathic literature) for treatment of various pathological syndromes ’.…”

“…Notably, articles about RADs usually appear not in journals of complementary medicine, but in apparently respectable journals, published by PLOS, Springer, Elsevier and so on. Due to the large amount of such papers (we found >100 only in English),1–24 we were unable to investigate all of them, but the articles that we did analyse contained misleading descriptions of active substance concentrations, severe flaws in study design and methodology, as well as concealed conflict of interests (COI). In the designated section, authors did not mention that MMH manufactures and sells RADs and holds the corresponding patents.…”

“…During the last fifteen years, numerous peer-reviewed journals published articles about the incredible properties of so-called release-active “drugs” (RADs) 1–24. It is claimed that these “drugs” are effective against tick-borne encephalitis, influenza, hemorrhagic fever with renal syndrome, meningococcal meningitis, herpes, HIV, and other viral and bacterial infections, diabetes, erectile dysfunction, sleep disorders, obesity, chronic inflammatory joint diseases, attention deficit hyperactivity disorder, chronic cerebral ischemia, benign prostatic hypertrophy, alcoholism, allergies, and many other health problems 18 25.…”

Preparation, Characterization and Studies of Physicochemical and Biological Properties of Drugs Coating Lactose in Fluidized Beds

“…Therapeutically, innovative drugs provide an advantage over existing methods of treatment in the case, for example, of relatively low doses when the desired effect is achieved, or when a drug contains substances of biotechnological originantibodies to specific antigen targets [14]. In recent years antibody preparations have found wide application in medicine due to targeting of pathophysiological causes of infectious, autoimmune, oncological and other socially significant diseases [15][16][17][18]. Taking into account the current world situation with regard to the rapid spread of respiratory infection, the development of new drugs aimed at targets important for virus reproduction as well as specific methods of quality control is relevant [19,20].…”